Published in Eur J Pharmacol on February 06, 2010
Opioid Analgesia in P450 Gene Cluster Knockout Mice: A Search for Analgesia-Relevant Isoforms. Drug Metab Dispos (2015) 0.75
Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther (1953) 5.14
Histamine in the nervous system. Physiol Rev (2008) 3.47
Properties of opiate-receptor binding in rat brain. Proc Natl Acad Sci U S A (1973) 3.34
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther (1993) 2.40
The pharmacology of cimetidine, a new histamine H2-receptor antagonist. Br J Pharmacol (1975) 1.51
Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. J Pharmacol Exp Ther (1996) 1.39
Specific binding of 3H-tiotidine to histamine H2 receptors in guinea pig cerebral cortex. Nature (1983) 1.37
The delta-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy. Pharmacol Rev (1999) 1.33
Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice. Brain Res (2000) 1.16
CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist. Neuropharmacology (2007) 1.02
Cimetidine: does neurotoxicity occur? Report of three cases. J R Soc Med (1979) 0.96
Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic. Neuropharmacology (2006) 0.96
Characterization of the antinociceptive properties of cimetidine and a structural analog. J Pharmacol Exp Ther (1996) 0.93
Role of histamine in rodent antinociception. Br J Pharmacol (1994) 0.92
Binding of [3H]cimetidine to rat brain tissue. Agents Actions (1980) 0.92
Improgan antinociception does not require neuronal histamine or histamine receptors. Brain Res (2003) 0.92
Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors. J Pharmacol Exp Ther (2002) 0.92
A third life for burimamide. Discovery and characterization of a novel class of non-opioid analgesics derived from histamine antagonists. Ann N Y Acad Sci (2000) 0.91
Simple cannula for repeated intracerebral drug administration in rats. Pharmacol Biochem Behav (1979) 0.91
Histamine H2-receptor binding with 3H-cimetidine in brain. Eur J Pharmacol (1978) 0.90
High-affinity binding of [3H]cimetidine to a heme-containing protein in rat brain. Drug Metab Dispos (2007) 0.89
Antinociceptive effect of centrally administered cimetidine and dimaprit in the rat. Pharmacology (1984) 0.87
3H-cimetidine and the H2-receptor. Life Sci (1983) 0.86
Homologous N-alkylnorketobemidones. Correlation of receptor binding with analgesic potency. J Med Chem (1975) 0.86
Properties of 3H-cimetidine binding in rat brain membrane fractions. Life Sci (1980) 0.85
Rodent antinociception following acute treatment with different histamine receptor agonists and antagonists. Pharmacol Biochem Behav (2002) 0.85
Absence of antinociceptive tolerance to improgan, a cimetidine analog, in rats. Brain Res (1998) 0.84
Histaminergic involvement in neuropathic pain produced by partial ligation of the sciatic nerve in rats. Reg Anesth Pain Med (2007) 0.83
Pain-relieving drugs and the brain histaminergic system: multiple analgesic mechanisms from histamine, improgan and cimetidine. Inflamm Res (2004) 0.83
Effects of cimetidine-like drugs on recombinant GABAA receptors. Life Sci (2004) 0.83
Opioid agonist affinity in the guinea-pig ileum and mouse vas deferens. Eur J Pharmacol (1990) 0.83
Novel qualitative structure-activity relationships for the antinociceptive actions of H2 antagonists, H3 antagonists and derivatives. J Pharmacol Exp Ther (1997) 0.83
Involvement of histamine in naloxone-resistant and naloxone-sensitive models of swim stress-induced antinociception in the mouse. Neuropharmacology (1991) 0.80
Cimetidine-induced seizures in mice. Antagonism by some GABAergic agents. Biochem Pharmacol (1993) 0.79
Neurotoxic convulsions induced by histamine H2 receptor antagonists in mice. Toxicol Appl Pharmacol (1996) 0.77
The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov (2005) 1.67
Diazepam-bound GABAA receptor models identify new benzodiazepine binding-site ligands. Nat Chem Biol (2012) 1.31
Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. J Med Chem (2011) 1.30
Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. Nat Neurosci (2010) 1.30
Pentameric ligand-gated ion channel ELIC is activated by GABA and modulated by benzodiazepines. Proc Natl Acad Sci U S A (2012) 1.22
Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. J Med Chem (2008) 1.20
Keynote review: histamine H3 receptor antagonists reach out for the clinic. Drug Discov Today (2005) 1.19
Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J Med Chem (2007) 1.18
Towards small-molecule CXCR3 ligands with clinical potential. ChemMedChem (2008) 1.11
Use of acetylcholine binding protein in the search for novel alpha7 nicotinic receptor ligands. In silico docking, pharmacological screening, and X-ray analysis. J Med Chem (2009) 1.11
Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Discov Today (2009) 1.09
Pain-facilitating medullary neurons contribute to opioid-induced respiratory depression. J Neurophysiol (2012) 1.07
Molecular and biochemical pharmacology of the histamine H4 receptor. Br J Pharmacol (2009) 1.06
Antiinflammatory and antinociceptive effects of the selective histamine H4-receptor antagonists JNJ7777120 and VUF6002 in a rat model of carrageenan-induced acute inflammation. Eur J Pharmacol (2007) 1.04
CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist. Neuropharmacology (2007) 1.02
Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis. J Am Chem Soc (2011) 1.00
Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1. J Med Chem (2012) 0.99
Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors. J Pharmacol Exp Ther (2008) 0.99
Asymmetric synthesis of synthetic alkaloids by a tandem biocatalysis/Ugi/Pictet-Spengler-type cyclization sequence. Chem Commun (Camb) (2010) 0.99
Cannabinoid-improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptor. Eur J Pharmacol (2006) 0.98
Discovery of quinazolines as histamine H4 receptor inverse agonists using a scaffold hopping approach. J Med Chem (2008) 0.98
Addressing the malaria drug resistance challenge using flow cytometry to discover new antimalarials. Bioorg Med Chem Lett (2009) 0.97
Sex- and histamine-dependent long-term cognitive effects of methamphetamine exposure. Neuropsychopharmacology (2006) 0.96
Synthesis and structure-activity relationship of the first nonpeptidergic inverse agonists for the human cytomegalovirus encoded chemokine receptor US28. J Med Chem (2005) 0.96
Activation of peripheral and spinal histamine H3 receptors inhibits formalin-induced inflammation and nociception, respectively. Pharmacol Biochem Behav (2007) 0.96
Online fluorescence enhancement assay for the acetylcholine binding protein with parallel mass spectrometric identification. J Med Chem (2010) 0.96
Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic. Neuropharmacology (2006) 0.96
A highly efficient synthesis of telaprevir by strategic use of biocatalysis and multicomponent reactions. Chem Commun (Camb) (2010) 0.94
Molecular determinants of ligand binding to H4R species variants. Mol Pharmacol (2010) 0.93
Improgan antinociception does not require neuronal histamine or histamine receptors. Brain Res (2003) 0.92
Phenylalanine 169 in the second extracellular loop of the human histamine H4 receptor is responsible for the difference in agonist binding between human and mouse H4 receptors. J Pharmacol Exp Ther (2008) 0.92
Discovery of novel Trypanosoma brucei phosphodiesterase B1 inhibitors by virtual screening against the unliganded TbrPDEB1 crystal structure. J Med Chem (2013) 0.91
The efficient one-pot reaction of up to eight components by the union of multicomponent reactions. Angew Chem Int Ed Engl (2009) 0.91
Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic. Pain (2011) 0.89
Identification of a novel scaffold for allosteric inhibition of wild type and drug resistant HIV-1 reverse transcriptase by fragment library screening. J Med Chem (2011) 0.89
High-affinity binding of [3H]cimetidine to a heme-containing protein in rat brain. Drug Metab Dispos (2007) 0.89
Discovery of S-(2-guanidylethyl)-isothiourea (VUF 8430) as a potent nonimidazole histamine H4 receptor agonist. J Med Chem (2006) 0.88
Development of a selective ESI-MS derivatization reagent: synthesis and optimization for the analysis of aldehydes in biological mixtures. Anal Chem (2008) 0.88
KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space. J Med Chem (2013) 0.88
Physiological basis for inhibition of morphine and improgan antinociception by CC12, a P450 epoxygenase inhibitor. J Neurophysiol (2010) 0.87
Pharmacological characterization of the new histamine H4 receptor agonist VUF 8430. Br J Pharmacol (2009) 0.87
CC12, a P450/epoxygenase inhibitor, acts in the rat rostral, ventromedial medulla to attenuate morphine antinociception. Brain Res (2013) 0.87
Acetylcholine binding protein (AChBP) as template for hierarchical in silico screening procedures to identify structurally novel ligands for the nicotinic receptors. Bioorg Med Chem (2011) 0.87
Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H₄ and the ion channel serotonin 5-HT₃A. Bioorg Med Chem Lett (2011) 0.86
Inhibition of chemical and low-intensity mechanical nociception by activation of histamine H3 receptors. J Pain (2005) 0.86
From heptahelical bundle to hits from the Haystack: structure-based virtual screening for GPCR ligands. Methods Enzymol (2013) 0.86
Design, synthesis, and structure-activity relationships of highly potent 5-HT₃ receptor ligands. J Med Chem (2012) 0.85
Major advances in the development of histamine H4 receptor ligands. Drug Discov Today (2009) 0.85
Impact of nicotine metabolism on nicotine's pharmacological effects and behavioral responses: insights from a Cyp2a(4/5)bgs-null mouse. J Pharmacol Exp Ther (2013) 0.85
Synthesis and pharmacological characterization of novel inverse agonists acting on the viral-encoded chemokine receptor US28. Bioorg Med Chem (2006) 0.85
Activation of spinal histamine H3 receptors inhibits mechanical nociception. Eur J Pharmacol (2003) 0.85
En route to new blockbuster anti-histamines: surveying the offspring of the expanding histamine receptor family. Trends Pharmacol Sci (2011) 0.85
Delineation of agonist binding to the human histamine H4 receptor using mutational analysis, homology modeling, and ab initio calculations. J Chem Inf Model (2008) 0.85
Identification of overlapping but differential binding sites for the high-affinity CXCR3 antagonists NBI-74330 and VUF11211. Mol Pharmacol (2013) 0.85
N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist. J Med Chem (2005) 0.84
Characterization of the histamine H4 receptor binding site. Part 1. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives. J Med Chem (2006) 0.84
Significance of cannabinoid CB1 receptors in improgan antinociception. J Pain (2007) 0.84
Virtual fragment screening: discovery of histamine H3 receptor ligands using ligand-based and protein-based molecular fingerprints. J Chem Inf Model (2012) 0.84
Assembly of a π-π stack of ligands in the binding site of an acetylcholine-binding protein. Nat Commun (2013) 0.84
Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase. Eur J Med Chem (2011) 0.84
Antinociceptive, brain-penetrating derivatives related to improgan, a non-opioid analgesic. Eur J Pharmacol (2005) 0.83
Effects of cimetidine-like drugs on recombinant GABAA receptors. Life Sci (2004) 0.83
Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists. Eur J Med Chem (2012) 0.83
Interaction kinetic and structural dynamic analysis of ligand binding to acetylcholine-binding protein. Biochemistry (2010) 0.82
Several down, a few to go: histamine H3 receptor ligands making the final push towards the market? Expert Opin Investig Drugs (2011) 0.82
Small and colorful stones make beautiful mosaics: fragment-based chemogenomics. Drug Discov Today (2012) 0.82
Development of a microfluidic confocal fluorescence detection system for the hyphenation of nano-LC to on-line biochemical assays. Anal Bioanal Chem (2010) 0.82
A new generation of anti-histamines: Histamine H4 receptor antagonists on their way to the clinic. Curr Opin Drug Discov Devel (2009) 0.82
Targeted LC-MS derivatization for aldehydes and carboxylic acids with a new derivatization agent 4-APEBA. Anal Bioanal Chem (2010) 0.81
Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature. Brain Res (2007) 0.81
Non-opioid antinociception produced by brain stem injections of improgan: significance of local, but not cross-regional, cannabinoid mechanisms. Brain Res (2008) 0.81
Crystal structure of the EphA4 protein tyrosine kinase domain in the apo- and dasatinib-bound state. FEBS Lett (2011) 0.81
CXCR3 antagonists: quaternary ammonium salts equipped with biphenyl- and polycycloaliphatic-anchors. Bioorg Med Chem (2011) 0.81
QUASI: a novel method for simultaneous superposition of multiple flexible ligands and virtual screening using partial similarity. J Chem Inf Model (2007) 0.80
Identification of novel α7 nicotinic receptor ligands by in silico screening against the crystal structure of a chimeric α7 receptor ligand binding domain. Bioorg Med Chem (2012) 0.80
From three-dimensional GPCR structure to rational ligand discovery. Adv Exp Med Biol (2014) 0.80
A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design. J Med Chem (2012) 0.79
Structure-based design, synthesis and structure-activity relationships of dibenzosuberyl- and benzoate-substituted tropines as ligands for acetylcholine-binding protein. Bioorg Med Chem Lett (2011) 0.79
Effects of acetylenic epoxygenase inhibitors on recombinant cytochrome p450s. Drug Metab Dispos (2011) 0.79
Synthesis and QSAR of quinazoline sulfonamides as highly potent human histamine H4 receptor inverse agonists. J Med Chem (2010) 0.79
Ligand based design of novel histamine H₄ receptor antagonists; fragment optimization and analysis of binding kinetics. Bioorg Med Chem Lett (2011) 0.79
TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity. PLoS One (2013) 0.78